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http://www.jdmdonline.com/content/13/1/35RESEARCH ARTICLE Open AccessGender differences in the association of insulin
resistance and high-sensitivity c-reactive protein
in obese adolescents
Ramin Alemzadeh1* and Jessica Kichler2Abstract
Background: Low-grade vascular inflammation is believed to initiate early atherosclerotic process by inducing
insulin resistance (IR), with significant gender differences in adults. We evaluated the relationship between surrogate
measures of inflammation and IR in obese adolescents.
Methods: The association among markers of inflammation [high-sensitivity c-reactive protein (hs-CRP)] and IR,
cardiometabolic risk factors and body composition was retrospectively examined in 199 obese adolescents
[(111 F/88 M), aged 15.5 ± 1.2 years]. Insulin resistance was assessed using homeostatic model assessment for
insulin resistance (HOMA-IR).
Results: Males had higher body mass index SD-score (BMI-SDS), fat mass (FM), glucose, insulin, HOMA-IR, HbA1c,
hs-CRP, triglycerides: HDL-C (TG:HDL-C) ratio than females (p < 0.05), whereas females had higher c-peptide: insulin
ratio than males (p < 0.05). Also, 50.8% of subjects were identified with metabolic syndrome with similar gender
distribution (M: 57.9% vs. F: 45.1%, p = 0.32). Hs-CRP was correlated with HOMA-IR in the cohort, even when controlling
for FM (r = 0.26; p < 0.0001). However, hs-CRP and HOMA-IR displayed a significant correlation only in females (r = 0.37;
p < 0.0001) when adjusting for FM and pubertal status. Also, c-peptide: insulin ratio was inversely correlated with
hs-CRP (r = −0.32; p < 0.001) and HOMA-IR (r = −0.62; p < 0.0001) and partially mediated the relationship between
these biomarkers only among females (β = 0.36, p < 0.001 to β = 0.18, p < 0.05; Sobel Test: p < 0.01).
Conclusions: A positive association between hs-CRP and HOMA-IR was observed only in adolescent girls which
was influenced by altered hepatic insulin clearance. This implies that obese adolescent girls may be at greatest risk
of developing early atherosclerosis and diabetes.
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Metabolic syndrome (MS) is a collection of metabolic
abnormalities that include visceral obesity, insulin re-
sistance (IR), hypertension, hypertriglyceridemia, a low
level of high-density lipoprotein cholesterol (HDL-C) and
hyperglycemia in adults and adolescents [1,2]. In individ-
uals with MS, IR plays a major role in the pathogenesis
of type 2 diabetes mellitus (T2DM) and cardiovascular
diseases [3,4]. An IR state is associated with low grade
inflammatory response characterized by abnormal produc-* Correspondence: ralemzad@uic.edu
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article, unless otherwise stated.tion of cytokines and the activations of pro-thrombotic and
pro-inflammatory signaling pathways which is associated
with an increased risk of T2DM, myocardial infarction and
stroke in adults [5-8].
Adipose tissue secretes a number of inflammatory cyto-
kines, such as interleukin-6 (IL-6), which induces hepatic
production of c-reactive protein (CRP), a known systemic
inflammatory biomarker. This systemic inflammatory
marker is also called high-sensitivity CRP (hs-CRP) when
measured in the serum with a high-sensitivity assay [9].
Indeed, several studies have shown that increased body
adiposity among children and adults is associated with
higher serum hs-CRP concentrations compared to normal-
weight individuals [10-12]. Also, obesity is associated withed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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known MS comorbidities in children, even prior to the
onset of puberty [13].
A strong association between hs-CRP and cardiovascu-
lar risk independent of other established risk factors, such
as dyslipidemia, blood pressure, alcohol consumption and
tobacco smoking in adults has been observed [14,15].
Similarly, circulating hs-CRP has been shown to be an
independent predictor of myocardial infarction, ische-
mic stroke, T2DM and hypertension in adults [15,16].
Also, elevated circulating hs-CRP level has been found
to correlate with early vascular endothelial dysfunction
among children and adolescents [17,18] suggesting that
inflammation plays a major role in the pathogenesis of
early atherosclerosis and likely begins in childhood with
progression slowly into adulthood [19,20].
Previous studies have shown that women have higher
hs-CRP levels than men, and this gender difference is
maintained across all ethnic groups [21-23]. While exact
mechanisms for this hs-CRP trend are not known, it is
possible that the gender difference in the relationship
between hs-CRP and obesity is due to relatively higher
degree of adiposity in women compared to men [22].
Specifically, the quantity and distribution of body fat
appear to influence hs-CRP levels to a greater extent in
women compared to men [24]. Also, all components of
MS may be more strongly associated with hs-CRP in
women compared to men suggesting that inflammatory
processes may play a strong role in the pathogenesis of
MS in women [25]. Thus, we hypothesized that this
gender difference in relationship between hs-CRP and
MS and its components is already present during ado-
lescence; and examined the association among markers
of inflammation, insulin resistance and insulin clearance
and adiposity in a group of obese adolescents.
Subjects and methods
Subjects and design
One hundred and ninety-nine adolescents (age: 13.2-19.9
years) who met the criteria for obesity [body mass index
(BMI) > 95th percentile for age] [26] were included in the
study. Subjects were evaluated at the Children’s Hospital
of Wisconsin (CHW) Endocrine Clinic for evaluation
of MS between February 2006 and October 2009. Race/
ethnicity was self-assigned: Caucasian (C, n = 87; 43.7%),
Mexican American [Hispanic (H), n = 60; 30.2%], and
African American (AA, n = 52; 26.1%). Children were
excluded if they had hepatic or renal disease, metabolic
rickets, malabsorptive disorders (e.g., Crohn’s disease,
cystic fibrosis, and/or celiac disease) or cancer, or were tak-
ing multivitamin supplements, anticonvulsants, or systemic
glucocorticoids. In compliance with the 1964 Declaration
of Helsinki, the CHW Institutional Review Board (IRB)approved the retrospective review of patients’ clinical
charts; thus, informed consent was not required.
Data were collected on patients including age, gender,
ethnicity, height, weight, blood pressure and body com-
position analysis by bioelectrical impedance (TANITA-
TBF-410, TANITA Corporation of America Inc., Arlington
Heights, IL) for evaluation of fat mass (FM), fat-free mass
(FFM) and total body water (TBW) [27,28]. Two well-
trained clinicians determined pubertal maturation (Tanner
stage). Fasting serum samples were obtained for glucose,
insulin, c-peptide, hemoglobin A1c (HbA1c), lipid profiles
and hs-CRP.
Laboratory studies and calculations
All blood samples were obtained between 0800 and 1100 h
after an overnight fast. Serum glucose was measured by an
autoanalyzer (Orthodiagnostics Fusion 5.1, Ortho-Diagnos-
tics, Rochester, NY). The hs-CRP assays were carried out
at Quest Diagnostics (San Jose, CA) using a polystyrene
particle-enhanced immunonephelometric method (Dade
Behring BNII). The detection limit of this assay was
0.20 mg/L with measuring range of 0.18 to 1150 mg/L
with intra-assay and inter-assay coefficients of variance of
2.65% and 3.6%, respectively. The hs-CRP values >10 mg/L
were excluded to avoid influence of acute infection [29].
Hemoglobin A1c (HbA1c) level was determined by the
Bayer DCA (Bayer Diagnostics Inc, Tarrytown, NY) 2000
instrument (non-diabetic range of 4.5% to 5.7%).
Fasting serum insulin was measured by Nichols radio-
immunoassay (RIA) (Nichols Institute, San Clemente, CA)
with intra-assay and inter-assay coefficients of variation
(CV) of 2.4-6.3% and 5.2-13.0%, respectively. The homeo-
static model assessment estimates for insulin resistance
(HOMA-IR) calculated as previously described [30]:
HOMA-IR = (blood glucose mmol/L × insulin μU/mL)/
22.5. Fasting serum c-peptide was measured by Nichols
radio-immunoassay (RIA) (Nichols Institute, San Clemente,
CA) with intra-assay and inter-assay coefficients of vari-
ation (CV) of 2.3-6.9% and 8.0-17.6%, respectively. Serum
c-peptide: insulin ratio was calculated as a surrogate marker
of hepatic insulin clearance.
Total cholesterol, high-density lipoprotein Cholesterol
(HDL-C) and triglycerides (TG) were determined by colori-
metric methods (Beckman spectrophotometer, Fullerton,
CA). Low-density lipoprotein cholesterol (LDL-C) was
calculated using Friedewald’s equation [31].
Blood pressure (BP) measurements were taken twice
and averaged with the patient in sitting position. Elevated
systolic or diastolic blood pressure (SBP or DBP) was de-
fined as a value above the 95th percentile for age, gender
and height [32].
Modified National Cholesterol Education Program
(NCEP) criteria [2] for the diagnosis of MS were de-
fined as the presence of 3 or more of the following:
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or diastolic BP > 90th percentile, age-adjusted TG >90th
percentile, age-adjusted HDL cholesterol <5th percentile,
and impaired fasting glucose >5.6 mmol/L.Statistical analysis
Statistical analyses were carried out using SPSS (version
14.0). Data are expressed as mean ± SD. Body mass
index (BMI) values were converted into standard deviation
scores (SDS), using 2000 Center for Disease Control
(CDC) growth charts. The natural logarithmic trans-
formation of the variables was used in the correlation
and regression analyses when they were found to be
skewed. Differences between those with MS versus
those who did not meet the MS criteria (non-MS) were
compared using unpaired student t tests. The differences
among ethnic subgroups were evaluated by one-way
analysis of variance (ANOVA), and Bonferroni’s post-hoc
testing was applied whenever appropriate. Chi-square ana-
lyses were used to compare prevalence of MS. Spearman’s
correlations were performed to examine the associations
between, HOMA-IR, hs-CRP, c-peptide, c-peptide: insulin
ratio, SBP, DBP, HbA1c, and the TG:HDL ratio for the
entire cohort. Partial correlations [i.e., controlling for fat
mass (FM) and Tanner levels] and multivariate linear
regression analyses [i.e., examination of the potential
mediating role of the c-peptide: insulin ratio on the rela-
tionship between the predictor variable (hs-CRP) and the
dependent variable (HOMA-IR)] and Sobel’s mediation
test [33,34] were performed for each gender cohort.
p <0.05 was considered significant.Results
Findings stratified by gender
Table 1 summarizes the clinical and biochemical charac-
teristics of the entire cohort as well as male and female
subgroups. The males had higher BMI-SDS, FM and FFM
than females (p < 0.05). While male adolescents had higher
fasting glucose, HbA1c, insulin, HOMA-IR, hs-CRP, TG
and TG:HDL-C ratio (p < 0.05) than females, the female
adolescents had similar c-peptide levels, but had higher
Tanner levels and c–peptide: insulin ratio than males
(p < 0.001).
The AA subgroup displayed significantly higher BMI-
SDS, FM and HbA1c than H and C subgroups (data not
shown, p < .0.01), whereas AA and H subgroups had
higher insulin levels than C subgroup (data not shown,
p < 0.01). In contrast, AA subgroup displayed signifi-
cantly lower serum c-peptide and c-peptide: insulin ratio
than H and C subgroups without racial/ethnic differ-
ences in hs-CRP and TG and TG: HDL-C ratio values
(data not shown).Findings stratified by presence and absence of metabolic
syndrome (MS)
While subjects with MS displayed higher BMI-SDS, FM,
fasting blood glucose, HbA1c, insulin, c-peptide, HOMA-IR,
hs-CRP, TG and TG: HDL-C ratio than the non-MS subjects
(data not shown; p < .0.01), they displayed lower c-peptide:
insulin ratio than the non-MS subjects (6.6 ± 2.7 vs. 7.4 ± 2.7,
p < 0.05). Also, the prevalence of MS was similar among
genders (M: 57.9% vs. F: 45.1%, p = NS) and racial/ethnic
subgroups (C: 23.6%, H: 16.1% and AA: 11.1%; p =NS).
Findings in the entire cohort
Table 2 provides a summary of the bivariate correlations
among the clinical and biochemical variables for the entire
cohort. Additional correlations between the clinical and
biochemical variables and FM found that SBP, hs-CRP,
HOMA-IR, TG: HDL-C, c-peptide and HbA1c showed
positive relationship with FM (p < 0.05), whereas c-peptide:
insulin ratio displayed an inverse relationship with FM
(p < 0.0001). While there were no gender differences
in the relationship of FM with hs-CRP, HOMA-IR,
TG: HDL-C ratio, c-peptide or the c-peptide: insulin
ratio, there were gender differences in the relationship
between FM and HbA1c [M: r = 0.36, p < 0.001) vs. F:
r = 0.16, p = 0.10; p < 0.0001].
Partial correlation findings in the male and female
cohorts when controlling for FM and tanner stages
In order to determine whether FM and pubertal status
was a potential mechanism through which gender influ-
ences the biomarkers of MS, subsequent partial correlation
analyses, which controlled for FM and Tanner levels, were
conducted for both males and females. Table 3 summarizes
partial correlations among the clinical and biochemical
variables for the entire cohort and both genders adjusted
for FM and Tanner stage. Both hs-CRP and HOMA-IR
showed positive relationships with the TG: HDL-C ratio,
c-peptide and HbA1c in the entire cohort after adjusting
for FM and Tanner stage (p < 0.01). In contrast, hs-CRP
and HOMA-IR displayed negative relationships with c-
peptide: insulin ratio (p < 0.01).
In males, only hs-CRP showed a significantly positive
relationship with the TG: HDL-C ratio (p < 0.0001), but
HOMA-IR had a negative relationship with c-peptide:
insulin ratio (p < 0.0001). In females, hs-CRP displayed
positive relationships with HOMA-IR, TG: HDL-C, c-
peptide and HbA1c (p < 0.05), whereas both hs-CRP and
HOMA-IR showed inverse relationships with the c-
peptide: insulin ratio (p < 0.001).
Multivariate regression findings in the male and
female cohorts
Multivariate linear regression analyses were conducted
separately for both genders. The regression analyses
Table 1 Clinical and biochemical characteristics of participants based on gender
Parameters All Males Females P
N (%) 199 88 (44.2) 111 (55.8) NA
Age (yrs) 15.5 ± 1.2 15.6 ± 1.1 15.5 ± 1.3 NS
Tanner stage 4.6 ± 0.5 4.5 ± 0.5 4.7 ± 0.4 <.0.001d
Race/ethnicity
Caucasians (%) 87 (43.7) 31 (35.2) 56 (50.5) NS
Hispanics (%) 60 (30.2) 31 (35.2) 29 (26.1) NS
African Americans (%) 52 (26.1) 26 (29.6) 26 (23.4) NS
SBP (mmHg) 127.7 ± 11.9 129.1 ± 11.1 126.6 ± 12.9 NS
DBP (mmHg) 69.1 ± 9.1 69.4 ± 9.2 68.8 ± 9.0 NS
BMI SDS 2.3 ± 0.4 2.5 ± 0.4 2.2 ± 0.3 <0.0001d
Fat (%) 43.8 ± 8.0 45.2 ± 9.8 42.7 ± 6.1 <0.05a
Fat Mass (kg) 47.1± 17.8 51.7 ± 20.2 43.4 ± 14.6 <0.001c
Fat-free Mass (kg) 57.8 ± 10.9 60.3 ± 13.7 55.9 ± 7.8 <0.01
FFM: FM Ratio 1.36 ± 0.4 1.31 ± 0.5 1.39 ± 0.3 NS
TBW (kg) 42.2 ± 8.0 43.9 ± 9.9 40.7 ± 5.7 NS
Glucose (mmol/L) 5.0 ± 0.5 5.1 ± 0.6 4.9 ± 0.4 <0.01b
HbA1c (%) 5.3 ± 0.4 5.4 ± 0.5 5.2 ± 0.4 <0.01
b
Insulin (pmol/L) 206.7 ± 92.2 244.2 ± 80.8 176.9 ± 90.2 <0.0001
HOMA-IR (mol uU/mL) 7.2 ± 3.7 8.1 ± 3.1 6.5 ± 3.4 <0.001c
c-peptide (pmol/L) 1302 ± 449.7 1337. 5 ± 430.5 1273.9 ± 464.3 NS
c-peptide: insulin ratio 7.1 ± 2.8 5.7 ± 1.6 8.1 ± 3.0 <0.0001d
hs-CRP (mg/L) 3.2 ± 1.4 5.4 ± 0.5 2.9 ± 1.2 <0.0001d
Triglycerides (mmol/L) 1.7 ± 0.9 1.9 ± 0.8 1.5 ± 0.9 <0.01b
Cholesterol (mmol/L) 4.6 ± 1.0 4.8 ± 0.9 4.5 ± 1.0 NS
HDL-C (mmol/L) 1.0 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 NS
LDL-C (mmol/L) 2.9 ± 0.8 2.9 ± 0.8 2.8 ± 0.9 NS
Triglycerides: HDL-C ratio 4.0 ± 2.6 4.4 ± 2.6 3.6 ± 2.5 <0.05a
Prevalence of MS (%) 50.8 57.9 45.1 NS
Not applicable (NA) and not significant (NS).
ap < 0.05, bp < 0.01, cp < 0.001and dp < 0.0001, for comparison of male vs. female group.
Table 2 Bivariate correlations for biomarkers of MS in the entire cohort















Fat mass (kg) 1.0 0.139a 0.066 0.451d 0.516d 0.148a 0.393d −0.332d 0.313d
SBP (mmHg) 1.0 0.464d 0.17a 0.076 0.053 −0.002 −0.121 0.119
DBP (mmHg) 1.0 0.073 0.087 0.074 0.082 −0.048 0.063
hs-CRP (mg/mL) 1.0 0.433d 0.368d 0.242c −0.425d 0.296d
HOMA-IR (mol uU/mL) 1.0 0.307d 0.592d −0.633d 0.370d
TG: HDL ratio 1.0 0.174a −0.199b 0.166a
c-peptide (pmol/L) 1.0 0.074 0.105
c-peptide: insulin ratio 1.0 −0.365d
HbA1c (%) 1.0
ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001.
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Table 3 Bivariate correlations for biomarkers of MS in the entire cohort and both genders adjusted for FM and
Tanner stage
SBP (mmHg) DBP (mmHg) hs-CRP (mg/L) HOMA-IR
(mol uU/mL)






Total 1.0 0.464d 0.170a 0.076 0.053 −0.002 −0.121 0.119
Male 1.0 0.444d 0.096 0.028 0.000 0.051 0.074 −0.003
Female 1.0 0.504d 0.097 −0.011 0.055 −0.133 −0.120 0.136
DBP (mmHg)
Total 1.0 0.073 0.087 0.074 0.082 −0.048 0.063
Male 1.0 0.036 −0.049 −0.016 −0.020 −0.025 −0.010
Female 1.0 0.147 0.095 0.114 0.134 −0.010 0.058
hs-CRP (mg/mL)
Total 1.0 0.433d 0.368d 0.240c −0.425d 0.296c
Male 1.0 0.141 0.411d 0.147 0.113 0.035
Female 1.0 0.362d 0.497d 0.187 −0.309c 0.211a
HOMA-IR (mol uU/mL)
Total 1.0 0.307d 0.592d −0.633d 0.370d
Male 1.0 0.210 0.256a −0.228a 0.008
Female 1.0 0.261b 0.670d −0.616d 0.357d
TG: HDL Ratio
Total 1.0 0.174a −0.199b 0.166a
Male 1.0 0.113 0.022 0.130
Female 1.0 0.170 −0.151 0.067
c-peptide (pmol/L)
Total 1.0 0.074. 0.105
Male 1.0 0.662d −0.153









ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001.
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insulin ratio (index of insulin clearance) on the rela-
tionship between the predictor variable (hs-CRP) and
the dependent variable (HOMA-IR), while controlling
for FM. This relationship was only found to be significant
among female participants (β = −0.54, t = −7.29, p < 0.001),
but not for male participants. In order to determine
the significance of this mediation model, the Sobel Test
yielded a partial mediation model for female participants
(β = 0.36, p < 0.001 to β = 0.18, p < 0.05; p < 0.01).Discussion
In the present study, hs-CRP and HOMA-IR were posi-
tively correlated in obese adolescents, but this relationship
remained significant only in females after controlling
for adiposity and pubertal status. We also found that
the hs-CRP and HOMA-IR association was influenced by
altered hepatic insulin clearance in females, especially after
controlling for adiposity. Additional findings from the
present study indicate that the c-peptide: insulin ratio
was inversely correlated with hs-CRP and HOMA-IR
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biomarkers only among females. These findings indicate
that there is a potential gender interaction for the associ-
ation between HOMA-IR and hs-CRP. Specifically, sex
hormones may play an important role in the inflammatory
mechanism and development of insulin resistance.
Research has shown a strong association between IR
and inflammation among adults [35], especially in obese
non-diabetic patients with visceral adipose tissue [36].
Further, the relationship between IR and inflammation
has been shown to have a stronger association in women
than men [25]. Although there is minimal research in
adolescents, the research thus far has found that adiposity
is a strong determinant of inflammation among non-obese
adolescents, with significant gender differences [37]. How-
ever, the quantity and distribution of FM influence inflam-
mation to a greater extent in women compared to men
[24]. In our study, hs-CRP was significantly correlated
with FM in both male and female adolescents, without
demonstrating any gender differences. Also, there were
no gender differences in the prevalence of MS, but
males had higher hs-CRP levels and HOMA-IR values
than females, likely due to higher FM in males. However,
positive relationship between hs-CRP and HOMA-IR for
the entire cohort demonstrated a gender difference, where
this relationship remained significant only in females after
controlling for FM. These findings suggest that although
adiposity plays a role in MS in both genders, female gen-
der is associated with additional risk for MS independent
of adiposity.
Chen et al. observed that fasting c-peptide was corre-
lated with several markers of MS in obese adults and
that basal c-peptide levels were significantly higher in
women as compared to men [38]. Also, high fasting c-
peptide level is a risk factor for atherosclerosis in both
non-diabetic and diabetic adults [39,40] and correlated
with components of MS in diabetic patients [39]. In our
study, there were no gender differences in basal c-peptide
levels, but c-peptide levels were significantly higher in
MS than non-MS group. Basal c-peptide was positively
correlated with FM and indices of inflammation (hs-
CRP and TG: HDL-C) and IR for the entire cohort.
Further, c-peptide remained positively correlated with
HOMA-IR after adjusting for FM in the entire cohort
and for both genders. However, the correlation between
HOMA-IR and c-peptide was greater in female than
male adolescents, suggesting a greater risk of athero-
sclerosis among females [41].
Decreased insulin clearance (c-peptide: insulin ratio) is
a common finding among AA subjects compared to
other racial/ethnic groups [42]. Additionally, it has been
shown that several indices of MS, (i.e., TG, SBP and waist
circumference) are associated with a decline of insulin
clearance rate among adults [43]. Further, it has beenshown that low grade inflammation induces insulin resist-
ance through altered insulin signaling in hepatocytes
and peripheral tissues [44]. Hepatic insulin clearance is
positively related to insulin sensitivity and negatively to
acute insulin response and adiposity across gender and
race/ethnicity [45]. In our study, we found that AA
subgroups had lower c-peptide: insulin ratios than C
and H subgroups. Male adolescents and those with MS
in the present study also demonstrated lower insulin
clearance rate than female adolescents and non-MS
subgroups, respectively. Insulin clearance was inversely
correlated with indices of inflammation, IR and HbA1c
and this relationship remained after adjusting for FM.
However, c-peptide: insulin ratio correlation with HOMA-
IR was stronger among females than males, with insulin
clearance partially mediating the relationship between
hs-CRP and HOMA-IR only in females.
Limitations to this study include: retrospective design as
well as lack of adiposity distribution data and oral glucose
tolerance data to assess glucose homeostasis, beta-cell
function and insulin clearance rate in relationship to
hs-CRP and HOMA-IR. Also, the accuracy of bioelectrical
impedance (BIA) for assessment of body composition
has been questioned because of larger errors in individual
estimates of body fat compared to DXA method [28].
However, BIA has been deemed accurate for assessing
body composition in large groups of normal weight or
obese pediatric subjects as compared to DXA [46]).
Another limitation to the study is that there were no
age- and sex-matched normal weight controls for each
racial/ethnic group.
In conclusion, only female adolescents demonstrated
an association between indices of inflammation and IR
when adjusting for adiposity. This relationship between
inflammation and IR was partially mediated by altered
hepatic insulin clearance for female adolescents only.
These findings imply that obese adolescent females may
be at the greatest risk of developing early atherosclerosis
and diabetes since decreasing insulin clearance inversely
mediates the relationship between inflammation and insu-
lin resistance independent of adiposity. Additional studies
are needed to evaluate the relationship between chronic
inflammation, IR, insulin clearance and development of
vascular endothelial dysfunction in obese adolescents.
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